Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "vrsta gradiva" (1) AND "polno besedilo" AND "organizacija" (Onkološki inštitut Ljubljana) .

61 - 70 / 4237
Na začetekNa prejšnjo stran3456789101112Na naslednjo stranNa konec
61.
62.
Advances in diagnostics and management of gestational trophoblastic disease
Nuša Lukinovič, Eva Pavla Malovrh, Iztok Takač, Monika Sobočan, Jure Knez, 2022, pregledni znanstveni članek

Objavljeno v DiRROS: 25.07.2024; Ogledov: 300; Prenosov: 190
.pdf Celotno besedilo (519,32 KB)
Gradivo ima več datotek! Več...

63.
Cardiac myxoma : single tertiary centre experience
Polona Kačar, Nejc Pavšič, Mojca Bervar, Zvezdana Dolenc-Stražar, Vesna Zadnik, Matija Jelenc, Katja Prokšelj, 2022, izvirni znanstveni članek

Objavljeno v DiRROS: 25.07.2024; Ogledov: 374; Prenosov: 111
.pdf Celotno besedilo (709,95 KB)

64.
65.
66.
Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma
Špela Koršič, Nastja Levašič, Rok Dežman, Lara Anja Lešnik Zupan, Blaž Trotovšek, Rado Janša, Lojze Šmid, Peter Popović, 2022, izvirni znanstveni članek

Povzetek: Background. Drug-eluting microsphere transarterial chemoembolization (DEM-TACE) is the standard of care in pa-tients with intermediate-stage hepatocellular carcinoma and ensures targeted and controlled cytotoxic and ischemic effects. Proper patient selection and optimized treatment techniques are associated with longer median survival. The aim of this single-institution retrospective study was to evaluate safety and efficacy of DEM-TACE under cone beam computed tomography (CBCT) control in patients with early and intermediate stagehepatocellular carcinoma.Patients and methods. A total of144 patients (mean age 67.9 ± 8.0 years, 127 males and 17 females) between February 2010 and December 2018 were studied. Microparticles of different dimensions according to two manufac-turers (diameter of 70–150 μm, 100–300 μm or 300–500 μm and 40-μm, 75-μm or 100-μm) were used and loaded with 50–150 mg of doxorubicin. The objective tumour response according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), the time to progression, adverse events and overall survival were (OS) evaluated.Results. In total, 452 procedures were performed (median, 3 per patient). Four (0.9% of all procedures) major com-plications were noted. Postembolization syndrome occurred after 35% of procedures. At the first imaging follow-up 2–3 months after first treatment, 91% of patients achieved an objective response. The median time to progression was 10.2 months (95% CI: 8.3-12.1 months). OS rates at 1, 2, 3, 4, and 5 years were 85%, 53%, 33%, 20% and 14%, respectively. The median survival time was 25.8 months (95% CI: 22.1–29.5 months). Conclusions. DEM-TACE under CBCT control in patients with early and intermediate stagehepatocellular carcinoma is a safe and effective method of treatment with high objective tumour response and survival rates.
Ključne besede: hepatocellular carcinoma, drug-eluting microspheres, doxorubicin
Objavljeno v DiRROS: 25.07.2024; Ogledov: 449; Prenosov: 182
.pdf Celotno besedilo (1,34 MB)
Gradivo ima več datotek! Več...

67.
Crystalloids vs. colloids for fluid optimization in patients undergoing brain tumour surgery
Jasmina Markovič Božič, Božidar Visočnik, Polona Mušič, Iztok Potočnik, Alenka Spindler-Vesel, 2022, izvirni znanstveni članek

Povzetek: Background. This randomised, double-blinded, single-centre study prospectively investigated the impact of goal directed therapy and fluid optimization with crystalloids or colloids on perioperative complications in patients un-dergoing brain tumour surgery. Main aim of the study was to investigate the impact of fluid type on postoperative complications.Patients and methods. 80 patients were allocated into two equal groups to be optimised with either crystalloids (n = 40) or colloids (n = 40). Invasive hemodynamic monitoring was used to adjust and maintain mean arterial pressure and cerebral oxygenation within the baseline values (± 20%) and stroke volume variation (SVV) ≤ 10%. Postoperative complications from different organ systems were monitored during the first 15 days after surgery. Hospital stay was also recorded.Results. Crystalloid group received significantly more fluids (p = 0.003) and phenylephrine (p = 0.02) compared to colloid group. This did not have any significant impact on perioperative complications and hospital stay, since no dif-ferences between groups were observed. Conclusions. Either crystalloids or colloids could be used for fluid optimization in brain tumour surgery. If protocol-ised perioperative haemodynamic management is used, the type of fluid does not have significant impact on the outcome.
Objavljeno v DiRROS: 25.07.2024; Ogledov: 336; Prenosov: 94
.pdf Celotno besedilo (618,86 KB)

68.
69.
Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
Marko Bitenc, Tanja Čufer, Izidor Kern, Martina Miklavčič, Sabrina Petrovič, Vida Groznik, Aleksander Sadikov, 2022, izvirni znanstveni članek

Povzetek: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. The present study evaluated outcomes of stage I–IIIA NSCLC patients treated with upfront radical surgery in everyday clinical practice, between 2010–2017. Data of 539 consecutive patients were retrieved from a prospective hospital-based registry. All diagnostic, treatment and follow-up procedures were performed at the same thoracic oncology centre according to the valid guidelines. The primary outcome was overall survival (OS) analysed by clinical(c) and pathological(p) TNM (tumour, node, metastases) stage. The impact of clinicopathological characteristics on OS was evaluated using univariable (UVA) and multivariable regression analysis (MVA). With a median follow-up of 53.9 months, median OS and 5-year OS rate in the overall population were 90.4 months and 64.4%. Five-year OS rates by pTNM stage I, II and IIIA were 70.2%, 60.21%, and 49.9%, respectively. Both cTNM and pTNM stages were associated with OS; but only pTNM retained its independent prognostic value (p = 0.003) in MVA. Agreement between cTNM and pTNM was 69.0%. Next to pTNM, age (p = 0.001) and gender (p = 0.004) retained their independent prognostic value for OS. The study showed favourable outcomes of resectable stage I–IIIA NSCLC treated with upfront surgery in real-life. Relatively low agreement between cTNM and pTNM stages and independent prognostic value of only pTNM, observed in real-life data, suggest that surgery remains the most accurate provider of the anatomical stage of disease and important upfront therapy.
Ključne besede: resectable NSCLC, upfront surgery, real-life data, overall survival, prognostic factors
Objavljeno v DiRROS: 25.07.2024; Ogledov: 321; Prenosov: 251
.pdf Celotno besedilo (747,28 KB)
Gradivo ima več datotek! Več...

70.
Iskanje izvedeno v 0.97 sek.
Na vrh